多发性硬化症改变病情药物的不良反应。

IF 1 Q4 NEUROSCIENCES Basic and Clinical Neuroscience Pub Date : 2023-11-01 DOI:10.32598/bcn.2021.2848.2
Maryam Salehbayat, Roya Abolfazli, Niayesh Mohebbi, Seyed Mehrdad Savar, Gloria Shalviri, Kheirollah Gholami
{"title":"多发性硬化症改变病情药物的不良反应。","authors":"Maryam Salehbayat, Roya Abolfazli, Niayesh Mohebbi, Seyed Mehrdad Savar, Gloria Shalviri, Kheirollah Gholami","doi":"10.32598/bcn.2021.2848.2","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>High frequency of adverse drug reactions (ADRs) challenges multiple sclerosis (MS) treatment. This study aims to assess the nature and frequency of ADRs induced by MS medications in an observational cross-sectional study.</p><p><strong>Methods: </strong>ADRs of all outpatients who had seen a neurologist and had received at least one disease-modifying therapy (DMT) for MS during the last three months were investigated.</p><p><strong>Results: </strong>A total of 484 ADRs were detected in these patients. The preventability rate was 5.9%, and 0.61% of reactions were serious.</p><p><strong>Conclusion: </strong>The high frequency of adverse drug reactions in this study shows a strong need for strategy planning to increase patients' adherence to treatment.</p><p><strong>Highlights: </strong>Adverse drug reactions (ADRs) are common in MS patients using disease modifying therapies.Such ADRs are more common in women than men.Various brand names of biosimilar disease-modifying therapy (DMT)s may have a different ADR profile.</p><p><strong>Plain language summary: </strong>Multiple sclerosis (MS) is a condition that can be managed by using disease modifying medications. Such medication could trigger an adverse reaction in the patients., affecting their commitment to the treatment. By identifying these adverse reactions and educating the MS patients about these reactions and how the adverse effects can be managed, healthcare providers can improve the treatment process. This study recorded the adverse drug reactions in 250 MS patients who were receiving the medication for at least three months. Most of the patients (76.4%) experienced some kind of adverse reaction. A bigger proportion of women experienced adverse reactions than men. About 84% of these reactions occurred within the first 3 hours of receiving the medication. Depending on the medication's brand name, the rate of adverse drug reactions were different in some cases. The results of this study point out the fact that experiencing adverse drug reactions is common in MS patients and these experiences could be different for each medication with a different brand name. Therefore, it is important for the healthcare providers to inform the patients about such reactions and the patients should seek all the information they need to manage these adverse effects by consulting their physician.</p>","PeriodicalId":8701,"journal":{"name":"Basic and Clinical Neuroscience","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11273197/pdf/","citationCount":"0","resultStr":"{\"title\":\"Adverse Drug Reactions of Multiple Sclerosis Disease-modifying Drugs.\",\"authors\":\"Maryam Salehbayat, Roya Abolfazli, Niayesh Mohebbi, Seyed Mehrdad Savar, Gloria Shalviri, Kheirollah Gholami\",\"doi\":\"10.32598/bcn.2021.2848.2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>High frequency of adverse drug reactions (ADRs) challenges multiple sclerosis (MS) treatment. This study aims to assess the nature and frequency of ADRs induced by MS medications in an observational cross-sectional study.</p><p><strong>Methods: </strong>ADRs of all outpatients who had seen a neurologist and had received at least one disease-modifying therapy (DMT) for MS during the last three months were investigated.</p><p><strong>Results: </strong>A total of 484 ADRs were detected in these patients. The preventability rate was 5.9%, and 0.61% of reactions were serious.</p><p><strong>Conclusion: </strong>The high frequency of adverse drug reactions in this study shows a strong need for strategy planning to increase patients' adherence to treatment.</p><p><strong>Highlights: </strong>Adverse drug reactions (ADRs) are common in MS patients using disease modifying therapies.Such ADRs are more common in women than men.Various brand names of biosimilar disease-modifying therapy (DMT)s may have a different ADR profile.</p><p><strong>Plain language summary: </strong>Multiple sclerosis (MS) is a condition that can be managed by using disease modifying medications. Such medication could trigger an adverse reaction in the patients., affecting their commitment to the treatment. By identifying these adverse reactions and educating the MS patients about these reactions and how the adverse effects can be managed, healthcare providers can improve the treatment process. This study recorded the adverse drug reactions in 250 MS patients who were receiving the medication for at least three months. Most of the patients (76.4%) experienced some kind of adverse reaction. A bigger proportion of women experienced adverse reactions than men. About 84% of these reactions occurred within the first 3 hours of receiving the medication. Depending on the medication's brand name, the rate of adverse drug reactions were different in some cases. The results of this study point out the fact that experiencing adverse drug reactions is common in MS patients and these experiences could be different for each medication with a different brand name. Therefore, it is important for the healthcare providers to inform the patients about such reactions and the patients should seek all the information they need to manage these adverse effects by consulting their physician.</p>\",\"PeriodicalId\":8701,\"journal\":{\"name\":\"Basic and Clinical Neuroscience\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11273197/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Basic and Clinical Neuroscience\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32598/bcn.2021.2848.2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic and Clinical Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32598/bcn.2021.2848.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

导言:高频率的药物不良反应(ADRs)对多发性硬化症(MS)的治疗提出了挑战。本研究旨在通过一项观察性横断面研究,评估多发性硬化症药物引起的不良反应的性质和频率:方法:对过去三个月中所有接受过神经科医生诊治并接受过至少一种疾病修饰疗法(DMT)治疗的多发性硬化症门诊患者的药物不良反应进行调查:结果:在这些患者中共发现了 484 例 ADR。可预防率为 5.9%,严重反应占 0.61%:结论:本研究中药物不良反应的发生率很高,这表明亟需制定战略规划来提高患者的治疗依从性:药物不良反应(ADRs)在使用疾病调整疗法的多发性硬化症患者中很常见,女性比男性更易发生此类不良反应。这些药物可能会引发患者的不良反应,影响他们对治疗的承诺。通过识别这些不良反应并教育多发性硬化症患者了解这些不良反应以及如何控制不良反应,医护人员可以改善治疗过程。这项研究记录了 250 名接受药物治疗至少三个月的多发性硬化症患者的药物不良反应。大多数患者(76.4%)都出现了某种不良反应。出现不良反应的女性比例高于男性。其中约 84% 的不良反应发生在服药后的最初 3 小时内。根据药物品牌的不同,药物不良反应的发生率也有所不同。这项研究结果表明,多发性硬化症患者出现药物不良反应是很常见的,而且每种不同品牌名称的药物可能会有不同的不良反应。因此,医疗服务提供者有必要告知患者这些不良反应,患者也应通过咨询医生来了解处理这些不良反应所需的所有信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Adverse Drug Reactions of Multiple Sclerosis Disease-modifying Drugs.

Introduction: High frequency of adverse drug reactions (ADRs) challenges multiple sclerosis (MS) treatment. This study aims to assess the nature and frequency of ADRs induced by MS medications in an observational cross-sectional study.

Methods: ADRs of all outpatients who had seen a neurologist and had received at least one disease-modifying therapy (DMT) for MS during the last three months were investigated.

Results: A total of 484 ADRs were detected in these patients. The preventability rate was 5.9%, and 0.61% of reactions were serious.

Conclusion: The high frequency of adverse drug reactions in this study shows a strong need for strategy planning to increase patients' adherence to treatment.

Highlights: Adverse drug reactions (ADRs) are common in MS patients using disease modifying therapies.Such ADRs are more common in women than men.Various brand names of biosimilar disease-modifying therapy (DMT)s may have a different ADR profile.

Plain language summary: Multiple sclerosis (MS) is a condition that can be managed by using disease modifying medications. Such medication could trigger an adverse reaction in the patients., affecting their commitment to the treatment. By identifying these adverse reactions and educating the MS patients about these reactions and how the adverse effects can be managed, healthcare providers can improve the treatment process. This study recorded the adverse drug reactions in 250 MS patients who were receiving the medication for at least three months. Most of the patients (76.4%) experienced some kind of adverse reaction. A bigger proportion of women experienced adverse reactions than men. About 84% of these reactions occurred within the first 3 hours of receiving the medication. Depending on the medication's brand name, the rate of adverse drug reactions were different in some cases. The results of this study point out the fact that experiencing adverse drug reactions is common in MS patients and these experiences could be different for each medication with a different brand name. Therefore, it is important for the healthcare providers to inform the patients about such reactions and the patients should seek all the information they need to manage these adverse effects by consulting their physician.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.60
自引率
0.00%
发文量
64
审稿时长
4 weeks
期刊介绍: BCN is an international multidisciplinary journal that publishes editorials, original full-length research articles, short communications, reviews, methodological papers, commentaries, perspectives and “news and reports” in the broad fields of developmental, molecular, cellular, system, computational, behavioral, cognitive, and clinical neuroscience. No area in the neural related sciences is excluded from consideration, although priority is given to studies that provide applied insights into the functioning of the nervous system. BCN aims to advance our understanding of organization and function of the nervous system in health and disease, thereby improving the diagnosis and treatment of neural-related disorders. Manuscripts submitted to BCN should describe novel results generated by experiments that were guided by clearly defined aims or hypotheses. BCN aims to provide serious ties in interdisciplinary communication, accessibility to a broad readership inside Iran and the region and also in all other international academic sites, effective peer review process, and independence from all possible non-scientific interests. BCN also tries to empower national, regional and international collaborative networks in the field of neuroscience in Iran, Middle East, Central Asia and North Africa and to be the voice of the Iranian and regional neuroscience community in the world of neuroscientists. In this way, the journal encourages submission of editorials, review papers, commentaries, methodological notes and perspectives that address this scope.
期刊最新文献
Investigating Combined Balance Training and Transcranial Direct Current Stimulation for the Recovery of Postural Control Following Chronic Stroke: A Study Protocol. Cognitive Rehabilitation for Adult Patients With Obsessive-compulsive Disorder: A Systematic Review of Randomized Controlled Trials. Comparing Various Types of Chronic Psychological Stress on Cognitive Functions and Behaviors in Rats. Feature Extraction With Stacked Autoencoders for EEG Channel Reduction in Emotion Recognition. fMRI-Based Multi-class DMDC Model Efficiently Decodes the Overlaps between ASD and ADHD.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1